{"gene":"NLRC5","run_date":"2026-06-10T05:19:52","timeline":{"discoveries":[{"year":2010,"finding":"NLRC5 inhibits NF-κB-dependent responses by directly interacting with IKKα and IKKβ and blocking their phosphorylation. It also interacts with RIG-I and MDA5 (but not MAVS) to inhibit RLR-mediated type I interferon responses. siRNA knockdown of NLRC5 enhanced NF-κB activation and type I interferon signaling.","method":"Co-immunoprecipitation, siRNA knockdown, reporter assays, phosphorylation assays in HEK293T and other cell lines","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP for IKKα/β and RIG-I/MDA5 interactions, phosphorylation blocking demonstrated, siRNA rescue experiments, replicated by multiple labs","pmids":["20434986"],"is_preprint":false},{"year":2010,"finding":"NLRC5 is an IFN-γ-inducible nuclear protein that associates with and activates the proximal promoters of MHC class I genes (chromatin immunoprecipitation). NLRC5 expression drives enhanced MHC class I expression and also induces β2-microglobulin, TAP, and LMP gene expression. Knockdown of NLRC5 specifically impaired IFN-γ-induced MHC class I upregulation.","method":"Chromatin immunoprecipitation (ChIP), reporter gene assays, siRNA knockdown, overexpression in lymphoid and epithelial cell lines","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — ChIP demonstrated direct promoter association, reporter assays showed transactivation, knockdown phenotype, independently replicated across multiple labs","pmids":["20639463"],"is_preprint":false},{"year":2010,"finding":"NLRC5 overexpression broadly dampens NF-κB-, AP-1-, and type I IFN-dependent signaling, most likely through transcriptional repression. NLRC5 shuttles between cytosol and nucleus in a CrmA-dependent manner. Knockdown in RAW264.7 macrophages potently upregulated proinflammatory responses and was also critical for LPS-induced IL-10 production.","method":"Overexpression and siRNA knockdown, reporter assays, subcellular fractionation/localization, cytokine ELISA in RAW264.7 macrophages","journal":"Journal of immunology (Baltimore, Md. : 1950)","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — multiple orthogonal methods (reporter assay, localization, KD phenotype) in single lab; nuclear shuttling shown but mechanism not deeply characterized","pmids":["20610642"],"is_preprint":false},{"year":2010,"finding":"NLRC5 is a cytosolic protein predominantly expressed in hematopoietic cells. Knockdown of endogenous NLRC5 reduced Sendai virus- and poly(I:C)-mediated type I interferon pathway responses in THP-1 cells and primary dermal fibroblasts, demonstrating a positive role in antiviral innate immunity. Overexpression alone did not trigger NF-κB or interferon pathways in HEK293T cells.","method":"siRNA knockdown, overexpression, qPCR, ELISA in THP-1 cells and primary fibroblasts","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — KD phenotype in two independent cell types, negative result for overexpression in HEK293T; single lab","pmids":["20538593"],"is_preprint":false},{"year":2010,"finding":"NLRC5 is upregulated by IFN-γ via a JAK/STAT-mediated autocrine signaling loop in human fibroblasts post-CMV infection. Overexpression and enforced oligomerization of NLRC5 activates IFN-γ activation sequence (GAS) and IFN-specific response element (ISRE) promoter elements and upregulates antiviral target genes (IFN-α, OAS1, PRKRIR).","method":"Reporter assays, siRNA knockdown, promoter analysis, overexpression/oligomerization experiments in human fibroblasts","journal":"Journal of immunology (Baltimore, Md. : 1950)","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — reporter assays and functional knockdown in relevant cell type; single lab with multiple methods","pmids":["20061403"],"is_preprint":false},{"year":2010,"finding":"NLRC5 knockdown nearly eliminated caspase-1, IL-1β, and IL-18 processing in response to bacterial infection, PAMPs, and DAMPs. NLRC5 reconstituted inflammasome activity with procaspase-1, pro-IL-1β, and ASC, showing cooperativity with NLRP3. NLRC5 biochemically associates with NLRP3 in a nucleotide-binding domain-dependent but LRR-inhibitory fashion.","method":"siRNA knockdown, reconstitution experiments, Co-immunoprecipitation, caspase-1 cleavage assays in human monocytic cells","journal":"Journal of immunology (Baltimore, Md. : 1950)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reconstitution of inflammasome activity plus Co-IP for NLRP3 interaction; single lab but multiple orthogonal methods","pmids":["21191067"],"is_preprint":false},{"year":2012,"finding":"NLRC5 deficiency in mice dramatically impaired basal MHC class I expression specifically in T, NKT, and NK lymphocytes (but only mildly affected APCs). Endogenous NLRC5 localized to the nucleus and occupied the proximal promoter region of H-2 genes by ChIP. NLRC5-mediated MHC I induction required both CARD and LRR domains. Nlrc5-deficient lymphocytes showed markedly reduced elimination by cytotoxic T cells.","method":"Nlrc5-deficient mouse generation, ChIP, domain mutagenesis, flow cytometry, cytotoxicity assays","journal":"Journal of immunology (Baltimore, Md. : 1950)","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — in vivo KO mouse phenotype, direct ChIP for nuclear promoter occupancy, domain requirement mapped; multiple orthogonal methods","pmids":["22412192"],"is_preprint":false},{"year":2012,"finding":"NLRC5 knockout mice show severe reduction in MHC class I and related genes (β2m, Tap1, Lmp2) but unaffected MHC class II. IFN-γ stimulation cannot overcome impaired MHC class I expression in Nlrc5-deficient cells. Upon Listeria monocytogenes infection, Nlrc5-deficient mice displayed impaired CD8+ T cell activation and increased bacterial loads.","method":"NLRC5 knockout mouse, qPCR, flow cytometry, infection models, CD8+ T cell activation assays","journal":"Journal of immunology (Baltimore, Md. : 1950)","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo KO with defined cellular and microbial phenotypes; independently replicated by multiple labs","pmids":["22711889"],"is_preprint":false},{"year":2012,"finding":"NLRC5 is specifically required in vivo for MHC class I gene expression and CD8+ T cell activation. NLRC5-deficient mice showed profound defects in MHC class I expression and failed to mount Listeria-specific CD8+ T cell responses. NLRP3-mediated inflammasome activation was also partially impaired in NLRC5-deficient mice. However, NLRC5 was dispensable for NF-κB-dependent proinflammatory genes and type I interferon induction.","method":"NLRC5-deficient mouse generation, infection models, flow cytometry, cytokine measurement, CD8+ T cell functional assays","journal":"Cell research","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo KO mouse with multiple defined phenotypes; independently corroborates findings from other labs","pmids":["22491475"],"is_preprint":false},{"year":2012,"finding":"NLRC5 knockout mice showed enhanced IKK and IRF3 phosphorylation in response to TLR stimulation or viral infection, with elevated IL-6 and IFN-β production in MEFs, macrophages, and in vivo. NLRC5 induction by TLR ligands or cytokines requires STAT1-mediated signaling.","method":"NLRC5 knockout mice, LPS/VSV challenge, phosphorylation assays, ELISA, STAT1 pathway inhibition","journal":"Cell research","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo KO with defined biochemical (phosphorylation) and cytokine phenotypes; replicated in multiple cell types","pmids":["22473004"],"is_preprint":false},{"year":2012,"finding":"NLRC5 knockdown in chicken HD11 macrophages reduced IFN-α and IFN-β expression after LPS or poly(I:C) stimulation, indicating a positive regulatory role for NLRC5 in type I interferon responses. No direct relationship was found between NLRC5 knockdown and IL-6 or MHC class I expression in this avian model.","method":"siRNA knockdown, qPCR in chicken HD11 macrophage cell line","journal":"BMC veterinary research","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single method (siRNA/qPCR) in avian cell line; single lab","pmids":["22401171"],"is_preprint":false},{"year":2012,"finding":"The nucleotide-binding domain (NBD) of NLRC5 is critical for both nuclear translocation and transactivation of MHC class I genes. An intact nuclear localization signal is required for NLRC5 nuclear import and MHC class I gene induction.","method":"Domain deletion/mutagenesis, subcellular localization imaging, MHC class I reporter assays","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional mutagenesis with localization and transcriptional readout; single lab","pmids":["22310711"],"is_preprint":false},{"year":2013,"finding":"Rhinovirus ion channel protein 2B targets the ER and Golgi to trigger Ca2+ flux, which activates NLRP3 and NLRC5 inflammasomes cooperatively, leading to IL-1β secretion in bronchial cells.","method":"Virus deletion mutants, siRNA knockdown, Ca2+ flux measurements, IL-1β secretion assays in primary bronchial cells","journal":"American journal of respiratory cell and molecular biology","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — virus mutants and siRNA in primary cells with defined readout; single lab","pmids":["23815151"],"is_preprint":false},{"year":2014,"finding":"NLRC5 binds RIG-I via its N-terminal death domain (atypical CARD). This interaction is critical for robust antiviral responses against influenza virus, as NLRC5 extends and stabilizes RIG-I expression. The influenza NS1 protein binds to NLRC5 to suppress its function. NLRC5's antiviral activity is LRR-domain independent.","method":"Co-immunoprecipitation, interaction domain mapping, overexpression in A549 and human bronchial epithelial cells, viral replication assays","journal":"European journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP with domain mapping and functional viral assays; single lab","pmids":["25404059"],"is_preprint":false},{"year":2014,"finding":"The solution NMR structure of the N-terminal effector domain of NLRC5 reveals a six α-helix bundle with a death fold. It is an atypical CARD (α-helix 3 replaced by a loop; α-helix 1 lacks characteristic interruption) with a distinct electrostatic surface. In vitro interaction experiments showed interaction with the tandem CARD of RIG-I.","method":"Solution NMR structure determination, in vitro interaction experiments","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — NMR structure with in vitro binding validation; single lab but rigorous structural method","pmids":["24815518"],"is_preprint":false},{"year":2015,"finding":"NLRC5 exclusively transactivates classical and non-classical MHC class I genes through binding to a specific SXY enhancer module distinct from that occupied by CIITA. NLRC5 chromatin recruitment requires the enhanceosome factor RFX5; Rfx5-knockout mice phenocopy Nlrc5 deficiency in MHC class I expression. The S-box sequence within the SXY module is the essential feature conferring NLRC5 specificity.","method":"ChIP-sequencing, Rfx5-knockout mice and cells, Nlrc5/CIIta double-knockout mice, de novo motif discovery, reporter assays","journal":"PLoS genetics","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — ChIP-seq with genetic KO validation, epistasis through double-KO mice, motif analysis and reporter confirmation; multiple orthogonal methods","pmids":["25811463"],"is_preprint":false},{"year":2015,"finding":"NLRC5 undergoes K63-linked ubiquitination by TRAF2/6 at lysine 1,178 following LPS stimulation, leading to dissociation of the NLRC5-IKK complex and creating a coherent feedforward loop to sensitize NF-κB activation. The deubiquitinase USP14 removes polyubiquitin chains from NLRC5, restoring NLRC5-mediated inhibition of NF-κB signaling.","method":"Ubiquitination assays, site-directed mutagenesis (K1178), Co-immunoprecipitation, mathematical modeling, USP14 overexpression/knockdown","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — site-specific mutagenesis identifying ubiquitination site, identification of E3 ligase (TRAF2/6) and deubiquitinase (USP14), multiple orthogonal biochemical methods","pmids":["26620909"],"is_preprint":false},{"year":2016,"finding":"NLRC5 promotes transcription of BTN3A1-3 genes through an atypical regulatory motif in their promoters, similar to MHC class I genes. Forced NLRC5 expression promotes BTN3A-dependent Vγ9Vδ2 T-cell-mediated killing of tumor cells.","method":"ChIP, reporter assays, NLRC5 overexpression in tumor cells, Vγ9Vδ2 T cell killing assays, BTN3A gene correlation analysis","journal":"iScience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP plus functional killing assay; single lab with multiple methods","pmids":["33364588"],"is_preprint":false},{"year":2019,"finding":"HIV-1 Tat-induced miRNA-34a targets NLRC5 mRNA (validated by Argonaute immunoprecipitation), downregulating NLRC5 protein and resulting in increased NF-κB p65 expression and microglial activation. miR-34a mimic downregulated NLRC5; miR-34a inhibitor upregulated NLRC5.","method":"Argonaute immunoprecipitation, bioinformatics, miRNA mimic/inhibitor transfection, in vivo validation in HIV-1 transgenic rats and SIV-infected macaques","journal":"Brain, behavior, and immunity","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Argonaute IP validation of miR-34a/NLRC5 interaction plus in vivo confirmation; single lab","pmids":["30872089"],"is_preprint":false},{"year":2020,"finding":"PRMT5 inhibits transcription of the NLRC5 gene in melanoma cells, thereby suppressing MHC class I antigen presentation. PRMT5 knockdown augmented NLRC5 expression and increased MHC class I abundance.","method":"PRMT5 knockdown/pharmacological inhibition (GSK3326595), gene expression analysis, MHC class I flow cytometry in melanoma cells","journal":"Science translational medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological and genetic inhibition of PRMT5 with defined NLRC5 transcriptional readout; single lab","pmids":["32641491"],"is_preprint":false},{"year":2021,"finding":"SARS-CoV-2 ORF6 protein suppresses NLRC5 both transcriptionally (by blocking STAT1 signaling, reducing IRF1 and NLRC5 gene expression) and functionally (by blocking karyopherin complex-dependent nuclear import of NLRC5), thereby inhibiting MHC class I pathway induction.","method":"SARS-CoV-2 ORF6 overexpression, gene expression profiling in COVID-19 patients and infected cell lines, nuclear import assays, STAT1 signaling analysis","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — two distinct molecular mechanisms identified (transcriptional via STAT1 and nuclear import via karyopherin), validated in patient samples and cell lines","pmids":["34782627"],"is_preprint":false},{"year":2021,"finding":"LC3 (autophagy protein) directly interacts with NLRC5 and inhibits NLRC5-mediated MHC class I antigen presentation pathway in endometrial cancer cells in vitro and in vivo. Autophagy upregulation correlates negatively with NLRC5 and MHC class I expression in endometrial cancer.","method":"Co-immunoprecipitation, autophagy modulation, MHC class I reporter assays, in vivo tumor model","journal":"Cancer letters","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — Co-IP for LC3-NLRC5 interaction with functional MHC-I readout in vivo and in vitro; single lab","pmids":["34974132"],"is_preprint":false},{"year":2022,"finding":"NLRC5 interacts with the dengue virus NS3 protease domain and recruits E3 ubiquitin ligase CUL2 to catalyze K48-linked poly-ubiquitination of NS3, which is then recognized by cargo receptor TOLLIP for selective autophagic degradation. This NLRC5-CUL2-NS3-TOLLIP axis restricts dengue virus infection.","method":"Co-immunoprecipitation, ubiquitination assays, autophagy inhibitors, NLRC5 knockout, overexpression, viral replication assays","journal":"Autophagy","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — full mechanistic axis defined (NLRC5→CUL2→K48-Ub-NS3→TOLLIP→autophagic degradation) with Co-IP, ubiquitination assays, and KO validation","pmids":["36126167"],"is_preprint":false},{"year":2022,"finding":"METTL3-mediated m6A modification of NLRC5 mRNA inhibits its YTHDF2-dependent degradation, thereby stabilizing NLRC5 and promoting MHC class I-mediated immunosurveillance in endometrial cancer. METTL3 depletion increased YTHDF2-dependent NLRC5 mRNA degradation.","method":"RNA immunoprecipitation (RIP), methylated RIP, RNA stability assays, METTL3 overexpression/depletion, YTHDF2 functional experiments, tumor mouse model","journal":"Biomarker research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — RIP and methylated-RIP with RNA stability and in vivo functional validation; single lab","pmids":["37085864"],"is_preprint":false},{"year":2022,"finding":"NLRC5 regulates IFNα-induced alternative splicing and expression of HLA class I and antigen presentation genes in human pancreatic β cells, indicating a role beyond transcriptional activation of MHC class I to include regulation of alternative splicing events.","method":"Bulk and single-cell RNA sequencing, NLRC5 gain/loss-of-function in EndoC-βH1 and human islet cells","journal":"Science advances","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — RNA-seq with functional NLRC5 manipulation; single lab, novel splicing function identified","pmids":["36103539"],"is_preprint":false},{"year":2023,"finding":"NLRC5 directly bound to NLRP3 and NLRC4 in inflammasomes (Co-IP) to cooperatively drive microglial pyroptosis (gasdermin D cleavage) and apoptosis. NLRC5 knockdown suppressed GSDMD cleavage, IL-1β and caspase-3 activation in a retinal ischemia model.","method":"Co-immunoprecipitation, NLRC5 knockdown, GSDMD/caspase-3/IL-1β assays in retinal ischemia model (in vivo and primary microglia)","journal":"Frontiers in cell and developmental biology","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — Co-IP for inflammasome complex interaction plus in vivo KD phenotype; single lab","pmids":["34095138"],"is_preprint":false},{"year":2023,"finding":"NLRC5 interacts with HSPA8 in macrophages and suppresses the NF-κB pathway. Myeloid-specific deletion of NLRC5 aggravated pressure overload-induced cardiac remodeling and promoted IL-6 secretion, affecting cardiomyocyte hypertrophy and cardiac fibroblast activation.","method":"Co-immunoprecipitation (NLRC5-HSPA8), myeloid-specific Nlrc5 conditional KO mice, pressure overload model, NF-κB pathway analysis, IL-6 ELISA","journal":"JACC. Basic to translational science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP identifies HSPA8 as binding partner, conditional KO with defined cardiac phenotype; single lab","pmids":["37325412"],"is_preprint":false},{"year":2024,"finding":"NLRC5 acts as an innate immune sensor driving PANoptosis (inflammatory cell death) in response to heme/PAMP and heme/cytokine combinations. NLRC5 interacted with NLRP12 and PANoptosome components to form a cell death complex. TLR signaling and NAD+ depletion regulated NLRC5 expression and ROS production to control PANoptosis. NLRC5-deficient mice were protected in hemolytic and inflammatory models.","method":"CRISPR-based NLRC5 knockout and reconstitution, Co-immunoprecipitation (NLRP12 and PANoptosome), cell death assays, ROS measurement, NLRC5-deficient mouse models","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — multiple orthogonal methods (KO, Co-IP, in vivo models), novel sensor function established in high-impact venue","pmids":["38878777"],"is_preprint":false},{"year":2022,"finding":"USP14, a deubiquitinase, stabilizes NLRC5 by preventing its proteasomal degradation, thereby enhancing NLRC5-mediated inhibition of NF-κB signaling in endothelial cells. USP14 overexpression in ApoE-/- mice reduced atherosclerotic lesions.","method":"USP14 overexpression/knockdown, Co-immunoprecipitation, ubiquitination assays, NF-κB pathway analysis, ApoE-/- mouse model","journal":"Biochimica et biophysica acta. Molecular and cell biology of lipids","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP and ubiquitination assays with in vivo validation; single lab","pmids":["36372300"],"is_preprint":false},{"year":2024,"finding":"USP14 promotes de-ubiquitination and stabilization of NLRC5, leading to Smad2/3 pathway activation and EndMT progression in atherosclerosis. USF1 transcriptionally activates USP14 to drive this USF1/USP14/NLRC5/Smad2/3 axis.","method":"Dual-luciferase reporter assay, ChIP, Co-immunoprecipitation, ubiquitination assays, shRNA knockdown, ApoE-/- mouse atherosclerosis model","journal":"Molecular medicine (Cambridge, Mass.)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP, Co-IP, and luciferase assays defining the USF1→USP14→NLRC5→Smad2/3 axis; in vivo confirmation; single lab","pmids":["38424494"],"is_preprint":false}],"current_model":"NLRC5 is a multifunctional NLR protein that serves as the master transcriptional coactivator (CITA) of MHC class I and related antigen-presentation genes (β2m, TAP1, LMP2, BTN3A) by localizing to the nucleus and binding SXY enhancer motifs via the RFX5-containing enhanceosome; it also negatively regulates NF-κB and type I interferon signaling by interacting with IKKα/β and RIG-I/MDA5 respectively, with its activity dynamically controlled by TRAF2/6-mediated K63-ubiquitination (at K1178) and USP14-mediated deubiquitination; additionally, NLRC5 can form inflammasome/PANoptosome complexes with NLRP3, NLRP12, and ASC to drive caspase-1-dependent IL-1β processing and PANoptosis, and it restricts dengue virus by recruiting E3 ligase CUL2 to ubiquitinate viral NS3 for TOLLIP-mediated selective autophagic degradation."},"narrative":{"mechanistic_narrative":"NLRC5 is a multifunctional NLR protein that serves as the master transcriptional coactivator of MHC class I antigen-presentation genes while also tuning innate immune signaling and inflammatory cell death [PMID:20639463, PMID:22412192, PMID:25811463]. As an IFN-γ-inducible nuclear protein whose own expression depends on STAT1-mediated signaling, NLRC5 occupies the proximal promoters of MHC class I genes and coordinately drives β2-microglobulin, TAP, and LMP expression [PMID:20639463, PMID:22412192, PMID:22473004]; its specificity arises from binding a distinct SXY enhancer module (notably the S-box) through the RFX5-containing enhanceosome, and Rfx5-knockout mice phenocopy Nlrc5 deficiency in MHC class I expression [PMID:25811463]. This transactivation requires an intact nucleotide-binding domain and nuclear localization signal for nuclear import as well as the CARD and LRR domains [PMID:22412192, PMID:22310711], and extends to non-classical MHC class I and butyrophilin (BTN3A) genes that license γδ T-cell killing [PMID:25811463, PMID:33364588]. Genetic ablation in mice profoundly reduces MHC class I, especially in lymphocytes, and cripples CD8+ T-cell responses to Listeria [PMID:22412192, PMID:22711889, PMID:22491475]. NLRC5 expression is itself a regulatory node controlled by PRMT5-mediated transcriptional repression, METTL3/YTHDF2 m6A-dependent mRNA stability, and miR-34a, and is targeted by viral immune evasion proteins including SARS-CoV-2 ORF6, which blocks both STAT1-driven induction and karyopherin-dependent nuclear import [PMID:32641491, PMID:37085864, PMID:30872089, PMID:34782627]. In parallel, NLRC5 negatively regulates NF-κB by directly binding IKKα/β to block their phosphorylation, an inhibitory interaction released by TRAF2/6-mediated K63-ubiquitination at K1178 and restored by USP14-mediated deubiquitination [PMID:20434986, PMID:26620909, PMID:36372300]. NLRC5 also functions in inflammatory cell death, cooperating with NLRP3 to support caspase-1/IL-1β processing and acting as an innate sensor that assembles with NLRP12 and PANoptosome components to drive PANoptosis in response to heme/PAMP stimuli [PMID:21191067, PMID:38878777]. Beyond immunity, NLRC5 restricts dengue virus by recruiting the E3 ligase CUL2 to K48-ubiquitinate the viral NS3 protease for TOLLIP-mediated selective autophagic degradation [PMID:36126167]. Reports of NLRC5 as a positive regulator of type I interferon responses conflict with knockout studies showing it is dispensable or inhibitory for type I IFN induction [PMID:20434986, PMID:20538593, PMID:22491475, PMID:22473004].","teleology":[{"year":2010,"claim":"Establishing whether NLRC5 functions as a brake on inflammatory signaling, the first studies showed it directly engages the IKK and RLR machinery to dampen NF-κB and type I interferon responses.","evidence":"Co-IP, siRNA knockdown, reporter and phosphorylation assays in HEK293T and other lines","pmids":["20434986"],"confidence":"High","gaps":["Did not reconcile with reports of NLRC5 as a positive antiviral regulator","Mechanism of IKK phosphorylation block not structurally defined"]},{"year":2010,"claim":"Defining NLRC5's nuclear function, it was identified as an IFN-γ-inducible nuclear factor that occupies MHC class I promoters and coordinately drives β2m, TAP, and LMP expression, establishing it as a transcriptional activator of antigen presentation.","evidence":"ChIP, reporter assays, siRNA knockdown and overexpression in lymphoid and epithelial lines","pmids":["20639463"],"confidence":"High","gaps":["Cis-element specificity not yet mapped","Co-factors mediating promoter recruitment unknown"]},{"year":2010,"claim":"Addressing whether NLRC5 also acts cytosolically in inflammasomes and antiviral sensing, studies reported cooperativity with NLRP3 for caspase-1/IL-1β processing and conflicting positive roles in type I IFN induction.","evidence":"Reconstitution, Co-IP, caspase-1 cleavage and qPCR/ELISA in monocytic cells, THP-1, and fibroblasts","pmids":["21191067","20538593","20610642","20061403"],"confidence":"Medium","gaps":["Positive versus negative roles in interferon signaling unresolved across cell types","Inflammasome contribution single-lab"]},{"year":2012,"claim":"To distinguish in vivo physiological function, knockout mice demonstrated NLRC5 is specifically required for MHC class I (not class II) expression and CD8+ T-cell responses, with lymphocytes most affected, while remaining largely dispensable for NF-κB and type I IFN.","evidence":"Multiple independent Nlrc5-deficient mouse lines, ChIP, domain mutagenesis, flow cytometry, Listeria infection","pmids":["22412192","22711889","22491475","22473004"],"confidence":"High","gaps":["Cell-type basis of differential MHC I dependence unexplained","KO data contradicted earlier positive IFN role reports"]},{"year":2012,"claim":"Mapping the domains required for activity, the NBD and an intact NLS were shown to be essential for nuclear import and MHC class I transactivation.","evidence":"Domain deletion/mutagenesis with localization imaging and reporter assays","pmids":["22310711"],"confidence":"Medium","gaps":["Karyopherin partners mediating import not identified","Single lab"]},{"year":2014,"claim":"Resolving the structural basis of NLRC5's effector domain and its antiviral engagement, NMR revealed an atypical CARD that binds the tandem CARD of RIG-I, an interaction targeted by influenza NS1.","evidence":"Solution NMR structure, in vitro binding, Co-IP and domain mapping in airway epithelial cells","pmids":["24815518","25404059"],"confidence":"High","gaps":["Functional consequence of RIG-I binding conflicts with negative regulation reports","Stoichiometry of NLRC5-RIG-I complex undefined"]},{"year":2015,"claim":"Determining the molecular basis of NLRC5 promoter specificity, ChIP-seq with genetic epistasis established that NLRC5 transactivates MHC class I exclusively via a distinct SXY/S-box module requiring the RFX5 enhanceosome.","evidence":"ChIP-seq, Rfx5-KO and Nlrc5/CIIta double-KO mice, motif discovery, reporter assays","pmids":["25811463"],"confidence":"High","gaps":["Direct DNA-binding versus enhanceosome-bridged recruitment not fully distinguished","Full enhanceosome subunit composition for NLRC5 not enumerated"]},{"year":2015,"claim":"Explaining how NLRC5's inhibitory activity is dynamically switched, K63-ubiquitination by TRAF2/6 at K1178 was shown to dissociate the NLRC5-IKK complex and sensitize NF-κB, with USP14 deubiquitination restoring inhibition.","evidence":"Site-directed mutagenesis, ubiquitination assays, Co-IP, mathematical modeling","pmids":["26620909"],"confidence":"High","gaps":["Spatial regulation of ubiquitination relative to nuclear pool unknown","Crosstalk with transcriptional function not addressed"]},{"year":2016,"claim":"Extending the transactivation program beyond classical MHC I, NLRC5 was shown to drive BTN3A1-3 expression and BTN3A-dependent Vγ9Vδ2 T-cell killing of tumor cells.","evidence":"ChIP, reporter assays, overexpression and γδ T-cell killing assays in tumor cells","pmids":["33364588"],"confidence":"Medium","gaps":["Whether BTN3A regulation uses the same S-box determinant not confirmed","Single lab"]},{"year":2024,"claim":"Establishing how NLRC5 protein and transcript levels are set, multiple regulatory inputs were defined: PRMT5 transcriptional repression, METTL3/YTHDF2 m6A-dependent mRNA stability, miR-34a targeting, and USP14-mediated proteasomal stabilization, the latter feeding NF-κB and Smad2/3 outputs in vascular disease.","evidence":"Knockdown/inhibition, RIP/meRIP, Argonaute IP, ChIP, ubiquitination assays in melanoma, endometrial cancer, microglia and ApoE-/- models","pmids":["32641491","37085864","30872089","36372300","38424494"],"confidence":"Medium","gaps":["Most regulatory axes shown in single disease contexts","Hierarchy among these inputs unknown"]},{"year":2024,"claim":"Defining NLRC5's roles in inflammatory cell death and viral restriction, it was shown to assemble with NLRP12/PANoptosome to sense heme/PAMP and drive PANoptosis, and to recruit CUL2 to K48-ubiquitinate dengue NS3 for TOLLIP-mediated autophagic degradation.","evidence":"CRISPR KO and reconstitution, Co-IP, cell death/ROS assays, ubiquitination assays, in vivo models","pmids":["38878777","36126167","34095138"],"confidence":"High","gaps":["How NLRC5 switches between nuclear transactivator and cytosolic sensor/scaffold roles is unresolved","Sensor ligand-binding mechanism for heme not structurally defined"]},{"year":null,"claim":"It remains unresolved how a single protein integrates its nuclear MHC class I transactivation, cytosolic NF-κB/RLR regulation, inflammasome/PANoptosome assembly, and antiviral ubiquitin-autophagy functions, and what governs the switch between these mutually exclusive activities.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified structural model of full-length NLRC5","Signal-dependent partitioning between nucleus and cytosol mechanistically undefined","Contradictory roles in type I IFN signaling unreconciled"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[1,6,15]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[1,6,15]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[0,16]},{"term_id":"GO:0140299","term_label":"molecular sensor activity","supporting_discovery_ids":[27]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[1,6,11]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[3,2]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[1,6,8]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[1,15]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,16]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[27,25]},{"term_id":"R-HSA-9612973","term_label":"Autophagy","supporting_discovery_ids":[22]}],"complexes":["RFX5 enhanceosome (SXY module)","NLRP3 inflammasome","PANoptosome (with NLRP12)"],"partners":["RFX5","IKKA","IKKB","RIG-I","NLRP3","USP14","CUL2","NLRP12"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q86WI3","full_name":"Protein NLRC5","aliases":["Caterpiller protein 16.1","CLR16.1","Nucleotide-binding oligomerization domain protein 27","Nucleotide-binding oligomerization domain protein 4"],"length_aa":1866,"mass_kda":204.6,"function":"Probable regulator of the NF-kappa-B and type I interferon signaling pathways. May also regulate the type II interferon signaling pathway. Plays a role in homeostatic control of innate immunity and in antiviral defense mechanisms","subcellular_location":"Cytoplasm","url":"https://www.uniprot.org/uniprotkb/Q86WI3/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/NLRC5","classification":"Not Classified","n_dependent_lines":2,"n_total_lines":1208,"dependency_fraction":0.0016556291390728477},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/NLRC5","total_profiled":1310},"omim":[{"mim_id":"613537","title":"NLR FAMILY, CASPASE RECRUITMENT DOMAIN-CONTAINING 5; NLRC5","url":"https://www.omim.org/entry/613537"},{"mim_id":"606636","title":"NLR FAMILY, PYRIN DOMAIN-CONTAINING 1; NLRP1","url":"https://www.omim.org/entry/606636"},{"mim_id":"605980","title":"NUCLEOTIDE-BINDING OLIGOMERIZATION DOMAIN PROTEIN 1; NOD1","url":"https://www.omim.org/entry/605980"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Cytosol","reliability":"Supported"},{"location":"Centrosome","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"bone marrow","ntpm":33.8},{"tissue":"lymphoid tissue","ntpm":31.8}],"url":"https://www.proteinatlas.org/search/NLRC5"},"hgnc":{"alias_symbol":["NOD27","CLR16.1","FLJ21709"],"prev_symbol":[]},"alphafold":{"accession":"Q86WI3","domains":[{"cath_id":"1.10.533.20","chopping":"8-81","consensus_level":"high","plddt":70.1526,"start":8,"end":81},{"cath_id":"3.40.50.300","chopping":"144-157_175-188_204-367","consensus_level":"high","plddt":77.1598,"start":144,"end":367},{"cath_id":"3.80.10.10","chopping":"639-782","consensus_level":"medium","plddt":83.4469,"start":639,"end":782},{"cath_id":"3.80.10,3.80.10","chopping":"788-818_845-948_977-998_1005-1079","consensus_level":"medium","plddt":74.9266,"start":788,"end":1079},{"cath_id":"-","chopping":"1111-1191","consensus_level":"medium","plddt":68.7633,"start":1111,"end":1191},{"cath_id":"3.80.10.10","chopping":"1436-1553","consensus_level":"medium","plddt":72.965,"start":1436,"end":1553},{"cath_id":"3.80.10.10","chopping":"1761-1853","consensus_level":"medium","plddt":87.3213,"start":1761,"end":1853},{"cath_id":"1.10.8","chopping":"368-432","consensus_level":"medium","plddt":79.7266,"start":368,"end":432}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q86WI3","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q86WI3-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q86WI3-F1-predicted_aligned_error_v6.png","plddt_mean":73.88},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=NLRC5","jax_strain_url":"https://www.jax.org/strain/search?query=NLRC5"},"sequence":{"accession":"Q86WI3","fasta_url":"https://rest.uniprot.org/uniprotkb/Q86WI3.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q86WI3/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q86WI3"}},"corpus_meta":[{"pmid":"20434986","id":"PMC_20434986","title":"NLRC5 negatively regulates the NF-kappaB and type I interferon signaling pathways.","date":"2010","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/20434986","citation_count":377,"is_preprint":false},{"pmid":"20639463","id":"PMC_20639463","title":"NLR family member NLRC5 is a transcriptional regulator of MHC class I genes.","date":"2010","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/20639463","citation_count":367,"is_preprint":false},{"pmid":"23175229","id":"PMC_23175229","title":"NLRC5: a key regulator of MHC class I-dependent immune responses.","date":"2012","source":"Nature reviews. Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/23175229","citation_count":313,"is_preprint":false},{"pmid":"27162338","id":"PMC_27162338","title":"NLRC5/MHC class I transactivator is a target for immune evasion in cancer.","date":"2016","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/27162338","citation_count":227,"is_preprint":false},{"pmid":"20610642","id":"PMC_20610642","title":"NLRC5 limits the activation of inflammatory pathways.","date":"2010","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/20610642","citation_count":202,"is_preprint":false},{"pmid":"32641491","id":"PMC_32641491","title":"PRMT5 control of cGAS/STING and NLRC5 pathways defines melanoma response to antitumor immunity.","date":"2020","source":"Science translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32641491","citation_count":199,"is_preprint":false},{"pmid":"21191067","id":"PMC_21191067","title":"Cutting edge: NLRC5-dependent activation of the inflammasome.","date":"2010","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/21191067","citation_count":179,"is_preprint":false},{"pmid":"20061403","id":"PMC_20061403","title":"The nucleotide-binding oligomerization domain-like receptor NLRC5 is involved in IFN-dependent antiviral immune responses.","date":"2010","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/20061403","citation_count":173,"is_preprint":false},{"pmid":"38878777","id":"PMC_38878777","title":"NLRC5 senses NAD+ depletion, forming a PANoptosome and driving PANoptosis and inflammation.","date":"2024","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/38878777","citation_count":156,"is_preprint":false},{"pmid":"20538593","id":"PMC_20538593","title":"A role for the human nucleotide-binding domain, leucine-rich repeat-containing family member NLRC5 in antiviral responses.","date":"2010","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20538593","citation_count":145,"is_preprint":false},{"pmid":"22412192","id":"PMC_22412192","title":"NLRC5 deficiency selectively impairs MHC class I- dependent lymphocyte killing by cytotoxic T cells.","date":"2012","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/22412192","citation_count":135,"is_preprint":false},{"pmid":"34782627","id":"PMC_34782627","title":"SARS-CoV-2 inhibits induction of the MHC class I pathway by targeting the STAT1-IRF1-NLRC5 axis.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/34782627","citation_count":135,"is_preprint":false},{"pmid":"23815151","id":"PMC_23815151","title":"Rhinovirus-induced calcium flux triggers NLRP3 and NLRC5 activation in bronchial cells.","date":"2013","source":"American journal of respiratory cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/23815151","citation_count":127,"is_preprint":false},{"pmid":"22491475","id":"PMC_22491475","title":"NLRC5 regulates MHC class I antigen presentation in host defense against intracellular pathogens.","date":"2012","source":"Cell research","url":"https://pubmed.ncbi.nlm.nih.gov/22491475","citation_count":125,"is_preprint":false},{"pmid":"22473004","id":"PMC_22473004","title":"Enhanced TLR-induced NF-κB signaling and type I interferon responses in NLRC5 deficient mice.","date":"2012","source":"Cell research","url":"https://pubmed.ncbi.nlm.nih.gov/22473004","citation_count":116,"is_preprint":false},{"pmid":"21148033","id":"PMC_21148033","title":"NLRC5 deficiency does not influence cytokine induction by virus and bacteria infections.","date":"2010","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/21148033","citation_count":98,"is_preprint":false},{"pmid":"22711889","id":"PMC_22711889","title":"Cutting edge: impaired MHC class I expression in mice deficient for Nlrc5/class I transactivator.","date":"2012","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/22711889","citation_count":91,"is_preprint":false},{"pmid":"25811463","id":"PMC_25811463","title":"NLRC5 exclusively transactivates MHC class I and related genes through a distinctive SXY module.","date":"2015","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/25811463","citation_count":83,"is_preprint":false},{"pmid":"28718425","id":"PMC_28718425","title":"NLRC5/CITA: A Key Player in Cancer Immune Surveillance.","date":"2017","source":"Trends in cancer","url":"https://pubmed.ncbi.nlm.nih.gov/28718425","citation_count":77,"is_preprint":false},{"pmid":"22209772","id":"PMC_22209772","title":"NLRC5: a newly discovered MHC class I transactivator (CITA).","date":"2011","source":"Microbes and infection","url":"https://pubmed.ncbi.nlm.nih.gov/22209772","citation_count":73,"is_preprint":false},{"pmid":"26975630","id":"PMC_26975630","title":"NLRC5 regulates cell proliferation, migration and invasion in hepatocellular carcinoma by targeting the Wnt/β-catenin signaling pathway.","date":"2016","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/26975630","citation_count":73,"is_preprint":false},{"pmid":"27471621","id":"PMC_27471621","title":"NLRC5 elicits antitumor immunity by enhancing processing and presentation of tumor antigens to CD8(+) T lymphocytes.","date":"2016","source":"Oncoimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/27471621","citation_count":71,"is_preprint":false},{"pmid":"32355214","id":"PMC_32355214","title":"Transcriptional Upregulation of NLRC5 by Radiation Drives STING- and Interferon-Independent MHC-I Expression on Cancer Cells and T Cell Cytotoxicity.","date":"2020","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/32355214","citation_count":66,"is_preprint":false},{"pmid":"30872089","id":"PMC_30872089","title":"HIV-1 Tat-mediated microglial inflammation involves a novel miRNA-34a-NLRC5-NFκB signaling axis.","date":"2019","source":"Brain, behavior, and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/30872089","citation_count":64,"is_preprint":false},{"pmid":"28784305","id":"PMC_28784305","title":"Dexmedetomidine (DEX) protects against hepatic ischemia/reperfusion (I/R) injury by suppressing inflammation and oxidative stress in NLRC5 deficient mice.","date":"2017","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/28784305","citation_count":59,"is_preprint":false},{"pmid":"25404059","id":"PMC_25404059","title":"NLRC5 interacts with RIG-I to induce a robust antiviral response against influenza virus infection.","date":"2014","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/25404059","citation_count":52,"is_preprint":false},{"pmid":"31207033","id":"PMC_31207033","title":"Knockdown of LncRNA SCAMP1 suppressed malignant biological behaviours of glioma cells via modulating miR-499a-5p/LMX1A/NLRC5 pathway.","date":"2019","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31207033","citation_count":52,"is_preprint":false},{"pmid":"26620909","id":"PMC_26620909","title":"Reversible ubiquitination shapes NLRC5 function and modulates NF-κB activation switch.","date":"2015","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/26620909","citation_count":51,"is_preprint":false},{"pmid":"29070585","id":"PMC_29070585","title":"NLRC5 deficiency ameliorates diabetic nephropathy through alleviating inflammation.","date":"2018","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/29070585","citation_count":51,"is_preprint":false},{"pmid":"22310711","id":"PMC_22310711","title":"The nucleotide-binding domain of NLRC5 is critical for nuclear import and transactivation activity.","date":"2012","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/22310711","citation_count":51,"is_preprint":false},{"pmid":"24319445","id":"PMC_24319445","title":"NLRC5, at the Heart of Antigen Presentation.","date":"2013","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/24319445","citation_count":50,"is_preprint":false},{"pmid":"26592197","id":"PMC_26592197","title":"NLRC5 regulates TGF-β1-induced proliferation and activation of hepatic stellate cells during hepatic fibrosis.","date":"2015","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/26592197","citation_count":49,"is_preprint":false},{"pmid":"28432942","id":"PMC_28432942","title":"Insights into the diversity of NOD-like receptors: Identification and expression analysis of NLRC3, NLRC5 and NLRX1 in rainbow trout.","date":"2017","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/28432942","citation_count":48,"is_preprint":false},{"pmid":"26861112","id":"PMC_26861112","title":"NLRC5 shields T lymphocytes from NK-cell-mediated elimination under inflammatory conditions.","date":"2016","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/26861112","citation_count":47,"is_preprint":false},{"pmid":"30644097","id":"PMC_30644097","title":"Long noncoding RNA MEG3 regulates rheumatoid arthritis by targeting NLRC5.","date":"2019","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/30644097","citation_count":47,"is_preprint":false},{"pmid":"23483478","id":"PMC_23483478","title":"Expression regulation and function of NLRC5.","date":"2013","source":"Protein & cell","url":"https://pubmed.ncbi.nlm.nih.gov/23483478","citation_count":43,"is_preprint":false},{"pmid":"25972545","id":"PMC_25972545","title":"Respiratory Syncytial Virus Infection Upregulates NLRC5 and Major Histocompatibility Complex Class I Expression through RIG-I Induction in Airway Epithelial Cells.","date":"2015","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/25972545","citation_count":42,"is_preprint":false},{"pmid":"30706093","id":"PMC_30706093","title":"Class I transactivator, NLRC5: a central player in the MHC class I pathway and cancer immune surveillance.","date":"2019","source":"Immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/30706093","citation_count":41,"is_preprint":false},{"pmid":"28499247","id":"PMC_28499247","title":"NLRC5 deficiency promotes myocardial damage induced by high fat diet in mice through activating TLR4/NF-κB.","date":"2017","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/28499247","citation_count":41,"is_preprint":false},{"pmid":"32010261","id":"PMC_32010261","title":"LncRNA MALAT1 prevents the protective effects of miR-125b-5p against acute myocardial infarction through positive regulation of NLRC5.","date":"2019","source":"Experimental and therapeutic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32010261","citation_count":41,"is_preprint":false},{"pmid":"32633419","id":"PMC_32633419","title":"MHC class I transactivator NLRC5 in host immunity, cancer and beyond.","date":"2020","source":"Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32633419","citation_count":39,"is_preprint":false},{"pmid":"30543814","id":"PMC_30543814","title":"NLRC5 mediates cell proliferation, migration, and invasion by regulating the Wnt/β-catenin signalling pathway in clear cell renal cell carcinoma.","date":"2018","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/30543814","citation_count":39,"is_preprint":false},{"pmid":"31434695","id":"PMC_31434695","title":"The deficiency of miR-214-3p exacerbates cardiac fibrosis via miR-214-3p/NLRC5 axis.","date":"2019","source":"Clinical science (London, England : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/31434695","citation_count":39,"is_preprint":false},{"pmid":"22024701","id":"PMC_22024701","title":"Regulation of immune pathways by the NOD-like receptor NLRC5.","date":"2011","source":"Immunobiology","url":"https://pubmed.ncbi.nlm.nih.gov/22024701","citation_count":38,"is_preprint":false},{"pmid":"33671123","id":"PMC_33671123","title":"The MHC Class-I Transactivator NLRC5: Implications to Cancer Immunology and Potential Applications to Cancer Immunotherapy.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33671123","citation_count":38,"is_preprint":false},{"pmid":"36103539","id":"PMC_36103539","title":"Transcription and splicing regulation by NLRC5 shape the interferon response in human pancreatic β cells.","date":"2022","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/36103539","citation_count":36,"is_preprint":false},{"pmid":"30867141","id":"PMC_30867141","title":"NLRC5: A paradigm for NLRs in immunological and inflammatory reaction.","date":"2019","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/30867141","citation_count":35,"is_preprint":false},{"pmid":"34974132","id":"PMC_34974132","title":"LC3 and NLRC5 interaction inhibits NLRC5-mediated MHC class I antigen presentation pathway in endometrial cancer.","date":"2021","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/34974132","citation_count":34,"is_preprint":false},{"pmid":"24445959","id":"PMC_24445959","title":"NLRC5 mediates cytokine secretion in RAW264.7 macrophages and modulated by the JAK2/STAT3 pathway.","date":"2014","source":"Inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/24445959","citation_count":34,"is_preprint":false},{"pmid":"29692724","id":"PMC_29692724","title":"The Long Non-coding RNA MEG3/miR-let-7c-5p Axis Regulates Ethanol-Induced Hepatic Steatosis and Apoptosis by Targeting NLRC5.","date":"2018","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/29692724","citation_count":34,"is_preprint":false},{"pmid":"29907459","id":"PMC_29907459","title":"NLRC5 deficiency protects against acute kidney injury in mice by mediating carcinoembryonic antigen-related cell adhesion molecule 1 signaling.","date":"2018","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/29907459","citation_count":33,"is_preprint":false},{"pmid":"22401171","id":"PMC_22401171","title":"NLRC5 knockdown in chicken macrophages alters response to LPS and poly (I:C) stimulation.","date":"2012","source":"BMC veterinary research","url":"https://pubmed.ncbi.nlm.nih.gov/22401171","citation_count":33,"is_preprint":false},{"pmid":"26806094","id":"PMC_26806094","title":"Role of NLRC5 in progression and reversal of hepatic fibrosis.","date":"2016","source":"Toxicology and applied pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/26806094","citation_count":31,"is_preprint":false},{"pmid":"27338800","id":"PMC_27338800","title":"NLRC5 promotes cell proliferation via regulating the AKT/VEGF-A signaling pathway in hepatocellular carcinoma.","date":"2016","source":"Toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/27338800","citation_count":31,"is_preprint":false},{"pmid":"34508321","id":"PMC_34508321","title":"MSCs-Derived Extracellular Vesicles Carrying miR-212-5p Alleviate Myocardial Infarction-Induced Cardiac Fibrosis via NLRC5/VEGF/TGF-β1/SMAD Axis.","date":"2021","source":"Journal of cardiovascular translational research","url":"https://pubmed.ncbi.nlm.nih.gov/34508321","citation_count":31,"is_preprint":false},{"pmid":"31824312","id":"PMC_31824312","title":"Emerging Roles for NLRC5 in Immune Diseases.","date":"2019","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/31824312","citation_count":30,"is_preprint":false},{"pmid":"36126167","id":"PMC_36126167","title":"NLRC5 restricts dengue virus infection by promoting the autophagic degradation of viral NS3 through E3 ligase CUL2 (cullin 2).","date":"2022","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/36126167","citation_count":30,"is_preprint":false},{"pmid":"29655162","id":"PMC_29655162","title":"Knockdown of NLRC5 attenuates renal I/R injury in vitro through the activation of PI3K/Akt signaling pathway.","date":"2018","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/29655162","citation_count":30,"is_preprint":false},{"pmid":"37072793","id":"PMC_37072793","title":"NOD-like receptor NLRC5 promotes neuroinflammation and inhibits neuronal survival in Parkinson's disease models.","date":"2023","source":"Journal of neuroinflammation","url":"https://pubmed.ncbi.nlm.nih.gov/37072793","citation_count":29,"is_preprint":false},{"pmid":"33547395","id":"PMC_33547395","title":"NLRC5/CITA expression correlates with efficient response to checkpoint blockade immunotherapy.","date":"2021","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/33547395","citation_count":29,"is_preprint":false},{"pmid":"28865311","id":"PMC_28865311","title":"NLRC5 promotes cell proliferation via regulating the NF-κB signaling pathway in Rheumatoid arthritis.","date":"2017","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/28865311","citation_count":29,"is_preprint":false},{"pmid":"24815518","id":"PMC_24815518","title":"Unusual structural features revealed by the solution NMR structure of the NLRC5 caspase recruitment domain.","date":"2014","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/24815518","citation_count":29,"is_preprint":false},{"pmid":"32774715","id":"PMC_32774715","title":"The lncRNA XIST promotes the progression of breast cancer by sponging miR-125b-5p to modulate NLRC5.","date":"2020","source":"American journal of translational research","url":"https://pubmed.ncbi.nlm.nih.gov/32774715","citation_count":29,"is_preprint":false},{"pmid":"37085864","id":"PMC_37085864","title":"METTL3 facilitates immunosurveillance by inhibiting YTHDF2-mediated NLRC5 mRNA degradation in endometrial cancer.","date":"2023","source":"Biomarker research","url":"https://pubmed.ncbi.nlm.nih.gov/37085864","citation_count":27,"is_preprint":false},{"pmid":"29408916","id":"PMC_29408916","title":"Investigation of single and synergic effects of NLRC5 and PD-L1 variants on the risk of colorectal cancer.","date":"2018","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/29408916","citation_count":27,"is_preprint":false},{"pmid":"34095138","id":"PMC_34095138","title":"The Regulatory NOD-Like Receptor NLRC5 Promotes Ganglion Cell Death in Ischemic Retinopathy by Inducing Microglial Pyroptosis.","date":"2021","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/34095138","citation_count":26,"is_preprint":false},{"pmid":"24044430","id":"PMC_24044430","title":"A molecular model of the full-length human NOD-like receptor family CARD domain containing 5 (NLRC5) protein.","date":"2013","source":"BMC bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/24044430","citation_count":26,"is_preprint":false},{"pmid":"27525969","id":"PMC_27525969","title":"Silencing NLRC5 inhibits extracellular matrix expression in keloid fibroblasts via inhibition of transforming growth factor-β1/Smad signaling pathway.","date":"2016","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/27525969","citation_count":26,"is_preprint":false},{"pmid":"31186034","id":"PMC_31186034","title":"The expression of NOD2, NLRP3 and NLRC5 and renal injury in anti-neutrophil cytoplasmic antibody-associated vasculitis.","date":"2019","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31186034","citation_count":25,"is_preprint":false},{"pmid":"30945291","id":"PMC_30945291","title":"NLRC5 negatively regulates LTA-induced inflammation via TLR2/NF-κB and participates in TLR2-mediated allergic airway inflammation.","date":"2019","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/30945291","citation_count":25,"is_preprint":false},{"pmid":"38424494","id":"PMC_38424494","title":"USF1 transcriptionally activates USP14 to drive atherosclerosis by promoting EndMT through NLRC5/Smad2/3 axis.","date":"2024","source":"Molecular medicine (Cambridge, Mass.)","url":"https://pubmed.ncbi.nlm.nih.gov/38424494","citation_count":24,"is_preprint":false},{"pmid":"32431202","id":"PMC_32431202","title":"NLRC5 promotes cell migration and invasion by activating the PI3K/AKT signaling pathway in endometrial cancer.","date":"2020","source":"The Journal of international medical research","url":"https://pubmed.ncbi.nlm.nih.gov/32431202","citation_count":24,"is_preprint":false},{"pmid":"27640334","id":"PMC_27640334","title":"Identification and expressional analysis of NLRC5 inflammasome gene in smolting Atlantic salmon (Salmo salar).","date":"2016","source":"Fish & shellfish immunology","url":"https://pubmed.ncbi.nlm.nih.gov/27640334","citation_count":24,"is_preprint":false},{"pmid":"33364588","id":"PMC_33364588","title":"NLRC5 promotes transcription of BTN3A1-3 genes and Vγ9Vδ2 T cell-mediated killing.","date":"2020","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/33364588","citation_count":23,"is_preprint":false},{"pmid":"29608899","id":"PMC_29608899","title":"Knockdown of NLRC5 inhibits renal fibroblast activation via modulating TGF-β1/Smad signaling pathway.","date":"2018","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/29608899","citation_count":23,"is_preprint":false},{"pmid":"32710960","id":"PMC_32710960","title":"NLRC5 negatively regulates inflammatory responses in LPS-induced acute lung injury through NF-κB and p38 MAPK signal pathways.","date":"2020","source":"Toxicology and applied pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/32710960","citation_count":23,"is_preprint":false},{"pmid":"37325412","id":"PMC_37325412","title":"Macrophage-Specific NLRC5 Protects From Cardiac Remodeling Through Interaction With HSPA8.","date":"2023","source":"JACC. Basic to translational science","url":"https://pubmed.ncbi.nlm.nih.gov/37325412","citation_count":22,"is_preprint":false},{"pmid":"31746301","id":"PMC_31746301","title":"miR-4319 Suppresses the Growth of Esophageal Squamous Cell Carcinoma Via Targeting NLRC5.","date":"2020","source":"Current molecular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/31746301","citation_count":22,"is_preprint":false},{"pmid":"33013364","id":"PMC_33013364","title":"NLRC5 Inhibits Inflammation of Secretory Phase Ectopic Endometrial Stromal Cells by Up-Regulating Autophagy in Ovarian Endometriosis.","date":"2020","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/33013364","citation_count":22,"is_preprint":false},{"pmid":"22613950","id":"PMC_22613950","title":"NLRC5: a NOD-like receptor protein with many faces in immune regulation.","date":"2012","source":"Cell research","url":"https://pubmed.ncbi.nlm.nih.gov/22613950","citation_count":22,"is_preprint":false},{"pmid":"32169428","id":"PMC_32169428","title":"Innate Immune Molecule NLRC5 Protects Mice From Helicobacter-induced Formation of Gastric Lymphoid Tissue.","date":"2020","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/32169428","citation_count":21,"is_preprint":false},{"pmid":"27876605","id":"PMC_27876605","title":"Role of zebrafish NLRC5 in antiviral response and transcriptional regulation of MHC related genes.","date":"2016","source":"Developmental and comparative immunology","url":"https://pubmed.ncbi.nlm.nih.gov/27876605","citation_count":21,"is_preprint":false},{"pmid":"27437103","id":"PMC_27437103","title":"NLRC5, a promising new entry in tumor immunology.","date":"2016","source":"Journal for immunotherapy of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/27437103","citation_count":21,"is_preprint":false},{"pmid":"25820389","id":"PMC_25820389","title":"NLRC5 Mediates IL-6 and IL-1β Secretion in LX-2 Cells and Modulated by the NF-κB/Smad3 Pathway.","date":"2015","source":"Inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/25820389","citation_count":21,"is_preprint":false},{"pmid":"28615208","id":"PMC_28615208","title":"Deficiency of the NOD-Like Receptor NLRC5 Results in Decreased CD8+ T Cell Function and Impaired Viral Clearance.","date":"2017","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/28615208","citation_count":21,"is_preprint":false},{"pmid":"32505342","id":"PMC_32505342","title":"NLRC5 deficiency ameliorates cardiac fibrosis in diabetic cardiomyopathy by regulating EndMT through Smad2/3 signaling pathway.","date":"2020","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/32505342","citation_count":20,"is_preprint":false},{"pmid":"36372300","id":"PMC_36372300","title":"USP14-mediated NLRC5 upregulation inhibits endothelial cell activation and inflammation in atherosclerosis.","date":"2022","source":"Biochimica et biophysica acta. Molecular and cell biology of lipids","url":"https://pubmed.ncbi.nlm.nih.gov/36372300","citation_count":19,"is_preprint":false},{"pmid":"31694750","id":"PMC_31694750","title":"Long noncoding RNA FER1L4 regulates rheumatoid arthritis via targeting NLRC5.","date":"2019","source":"Clinical and experimental rheumatology","url":"https://pubmed.ncbi.nlm.nih.gov/31694750","citation_count":19,"is_preprint":false},{"pmid":"31900803","id":"PMC_31900803","title":"Promotion on NLRC5 upregulating MHC-I expression by IFN-γ in MHC-I-deficient breast cancer cells.","date":"2019","source":"Immunologic research","url":"https://pubmed.ncbi.nlm.nih.gov/31900803","citation_count":19,"is_preprint":false},{"pmid":"29394898","id":"PMC_29394898","title":"Methylation of the genes ROD1, NLRC5, and HKR1 is associated with aging in Hainan centenarians.","date":"2018","source":"BMC medical genomics","url":"https://pubmed.ncbi.nlm.nih.gov/29394898","citation_count":19,"is_preprint":false},{"pmid":"30559222","id":"PMC_30559222","title":"The Obligate Intracellular Bacterium Orientia tsutsugamushi Targets NLRC5 To Modulate the Major Histocompatibility Complex Class I Pathway.","date":"2019","source":"Infection and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/30559222","citation_count":19,"is_preprint":false},{"pmid":"31925644","id":"PMC_31925644","title":"NLRC5: new cancer buster?","date":"2020","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/31925644","citation_count":18,"is_preprint":false},{"pmid":"35174769","id":"PMC_35174769","title":"Selective autophagy of NLRC5 promotes immune evasion of endometrial cancer.","date":"2022","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/35174769","citation_count":18,"is_preprint":false},{"pmid":"33090288","id":"PMC_33090288","title":"Arid2-IR promotes NF-κB-mediated renal inflammation by targeting NLRC5 transcription.","date":"2020","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/33090288","citation_count":18,"is_preprint":false},{"pmid":"28713900","id":"PMC_28713900","title":"NLRC5 silencing ameliorates cardiac fibrosis by inhibiting the TGF‑β1/Smad3 signaling pathway.","date":"2017","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/28713900","citation_count":18,"is_preprint":false},{"pmid":"32790491","id":"PMC_32790491","title":"NLRC5 alleviated OGD/R-induced PC12-cell injury by inhibiting activation of the TLR4/MyD88/NF-κB pathway.","date":"2020","source":"The Journal of international medical research","url":"https://pubmed.ncbi.nlm.nih.gov/32790491","citation_count":17,"is_preprint":false},{"pmid":"34536366","id":"PMC_34536366","title":"LncRNA MEG3 reverses CCl4-induced liver fibrosis by targeting NLRC5.","date":"2021","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/34536366","citation_count":16,"is_preprint":false},{"pmid":"28122660","id":"PMC_28122660","title":"NLRC5 polymorphism is associated with susceptibility to chronic periodontitis.","date":"2017","source":"Immunobiology","url":"https://pubmed.ncbi.nlm.nih.gov/28122660","citation_count":16,"is_preprint":false},{"pmid":"34220868","id":"PMC_34220868","title":"NLRC5: A Potential Target for Central Nervous System Disorders.","date":"2021","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/34220868","citation_count":15,"is_preprint":false},{"pmid":"33797607","id":"PMC_33797607","title":"NLRC5 regulates expression of MHC-I and provides a target for anti-tumor immunity in transmissible cancers.","date":"2021","source":"Journal of cancer research and clinical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/33797607","citation_count":15,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":49052,"output_tokens":7638,"usd":0.130863,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":17074,"output_tokens":4531,"usd":0.099322,"stage2_stop_reason":"end_turn"},"total_usd":0.230185,"stage1_batch_id":"msgbatch_013a8chtv3AWyTqv4z4sEF4C","stage2_batch_id":"msgbatch_01AHsuW63vinsvuTgzmQ3n62","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2010,\n      \"finding\": \"NLRC5 inhibits NF-κB-dependent responses by directly interacting with IKKα and IKKβ and blocking their phosphorylation. It also interacts with RIG-I and MDA5 (but not MAVS) to inhibit RLR-mediated type I interferon responses. siRNA knockdown of NLRC5 enhanced NF-κB activation and type I interferon signaling.\",\n      \"method\": \"Co-immunoprecipitation, siRNA knockdown, reporter assays, phosphorylation assays in HEK293T and other cell lines\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP for IKKα/β and RIG-I/MDA5 interactions, phosphorylation blocking demonstrated, siRNA rescue experiments, replicated by multiple labs\",\n      \"pmids\": [\"20434986\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"NLRC5 is an IFN-γ-inducible nuclear protein that associates with and activates the proximal promoters of MHC class I genes (chromatin immunoprecipitation). NLRC5 expression drives enhanced MHC class I expression and also induces β2-microglobulin, TAP, and LMP gene expression. Knockdown of NLRC5 specifically impaired IFN-γ-induced MHC class I upregulation.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP), reporter gene assays, siRNA knockdown, overexpression in lymphoid and epithelial cell lines\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — ChIP demonstrated direct promoter association, reporter assays showed transactivation, knockdown phenotype, independently replicated across multiple labs\",\n      \"pmids\": [\"20639463\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"NLRC5 overexpression broadly dampens NF-κB-, AP-1-, and type I IFN-dependent signaling, most likely through transcriptional repression. NLRC5 shuttles between cytosol and nucleus in a CrmA-dependent manner. Knockdown in RAW264.7 macrophages potently upregulated proinflammatory responses and was also critical for LPS-induced IL-10 production.\",\n      \"method\": \"Overexpression and siRNA knockdown, reporter assays, subcellular fractionation/localization, cytokine ELISA in RAW264.7 macrophages\",\n      \"journal\": \"Journal of immunology (Baltimore, Md. : 1950)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — multiple orthogonal methods (reporter assay, localization, KD phenotype) in single lab; nuclear shuttling shown but mechanism not deeply characterized\",\n      \"pmids\": [\"20610642\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"NLRC5 is a cytosolic protein predominantly expressed in hematopoietic cells. Knockdown of endogenous NLRC5 reduced Sendai virus- and poly(I:C)-mediated type I interferon pathway responses in THP-1 cells and primary dermal fibroblasts, demonstrating a positive role in antiviral innate immunity. Overexpression alone did not trigger NF-κB or interferon pathways in HEK293T cells.\",\n      \"method\": \"siRNA knockdown, overexpression, qPCR, ELISA in THP-1 cells and primary fibroblasts\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — KD phenotype in two independent cell types, negative result for overexpression in HEK293T; single lab\",\n      \"pmids\": [\"20538593\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"NLRC5 is upregulated by IFN-γ via a JAK/STAT-mediated autocrine signaling loop in human fibroblasts post-CMV infection. Overexpression and enforced oligomerization of NLRC5 activates IFN-γ activation sequence (GAS) and IFN-specific response element (ISRE) promoter elements and upregulates antiviral target genes (IFN-α, OAS1, PRKRIR).\",\n      \"method\": \"Reporter assays, siRNA knockdown, promoter analysis, overexpression/oligomerization experiments in human fibroblasts\",\n      \"journal\": \"Journal of immunology (Baltimore, Md. : 1950)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — reporter assays and functional knockdown in relevant cell type; single lab with multiple methods\",\n      \"pmids\": [\"20061403\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"NLRC5 knockdown nearly eliminated caspase-1, IL-1β, and IL-18 processing in response to bacterial infection, PAMPs, and DAMPs. NLRC5 reconstituted inflammasome activity with procaspase-1, pro-IL-1β, and ASC, showing cooperativity with NLRP3. NLRC5 biochemically associates with NLRP3 in a nucleotide-binding domain-dependent but LRR-inhibitory fashion.\",\n      \"method\": \"siRNA knockdown, reconstitution experiments, Co-immunoprecipitation, caspase-1 cleavage assays in human monocytic cells\",\n      \"journal\": \"Journal of immunology (Baltimore, Md. : 1950)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reconstitution of inflammasome activity plus Co-IP for NLRP3 interaction; single lab but multiple orthogonal methods\",\n      \"pmids\": [\"21191067\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"NLRC5 deficiency in mice dramatically impaired basal MHC class I expression specifically in T, NKT, and NK lymphocytes (but only mildly affected APCs). Endogenous NLRC5 localized to the nucleus and occupied the proximal promoter region of H-2 genes by ChIP. NLRC5-mediated MHC I induction required both CARD and LRR domains. Nlrc5-deficient lymphocytes showed markedly reduced elimination by cytotoxic T cells.\",\n      \"method\": \"Nlrc5-deficient mouse generation, ChIP, domain mutagenesis, flow cytometry, cytotoxicity assays\",\n      \"journal\": \"Journal of immunology (Baltimore, Md. : 1950)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — in vivo KO mouse phenotype, direct ChIP for nuclear promoter occupancy, domain requirement mapped; multiple orthogonal methods\",\n      \"pmids\": [\"22412192\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"NLRC5 knockout mice show severe reduction in MHC class I and related genes (β2m, Tap1, Lmp2) but unaffected MHC class II. IFN-γ stimulation cannot overcome impaired MHC class I expression in Nlrc5-deficient cells. Upon Listeria monocytogenes infection, Nlrc5-deficient mice displayed impaired CD8+ T cell activation and increased bacterial loads.\",\n      \"method\": \"NLRC5 knockout mouse, qPCR, flow cytometry, infection models, CD8+ T cell activation assays\",\n      \"journal\": \"Journal of immunology (Baltimore, Md. : 1950)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo KO with defined cellular and microbial phenotypes; independently replicated by multiple labs\",\n      \"pmids\": [\"22711889\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"NLRC5 is specifically required in vivo for MHC class I gene expression and CD8+ T cell activation. NLRC5-deficient mice showed profound defects in MHC class I expression and failed to mount Listeria-specific CD8+ T cell responses. NLRP3-mediated inflammasome activation was also partially impaired in NLRC5-deficient mice. However, NLRC5 was dispensable for NF-κB-dependent proinflammatory genes and type I interferon induction.\",\n      \"method\": \"NLRC5-deficient mouse generation, infection models, flow cytometry, cytokine measurement, CD8+ T cell functional assays\",\n      \"journal\": \"Cell research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo KO mouse with multiple defined phenotypes; independently corroborates findings from other labs\",\n      \"pmids\": [\"22491475\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"NLRC5 knockout mice showed enhanced IKK and IRF3 phosphorylation in response to TLR stimulation or viral infection, with elevated IL-6 and IFN-β production in MEFs, macrophages, and in vivo. NLRC5 induction by TLR ligands or cytokines requires STAT1-mediated signaling.\",\n      \"method\": \"NLRC5 knockout mice, LPS/VSV challenge, phosphorylation assays, ELISA, STAT1 pathway inhibition\",\n      \"journal\": \"Cell research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo KO with defined biochemical (phosphorylation) and cytokine phenotypes; replicated in multiple cell types\",\n      \"pmids\": [\"22473004\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"NLRC5 knockdown in chicken HD11 macrophages reduced IFN-α and IFN-β expression after LPS or poly(I:C) stimulation, indicating a positive regulatory role for NLRC5 in type I interferon responses. No direct relationship was found between NLRC5 knockdown and IL-6 or MHC class I expression in this avian model.\",\n      \"method\": \"siRNA knockdown, qPCR in chicken HD11 macrophage cell line\",\n      \"journal\": \"BMC veterinary research\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single method (siRNA/qPCR) in avian cell line; single lab\",\n      \"pmids\": [\"22401171\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"The nucleotide-binding domain (NBD) of NLRC5 is critical for both nuclear translocation and transactivation of MHC class I genes. An intact nuclear localization signal is required for NLRC5 nuclear import and MHC class I gene induction.\",\n      \"method\": \"Domain deletion/mutagenesis, subcellular localization imaging, MHC class I reporter assays\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional mutagenesis with localization and transcriptional readout; single lab\",\n      \"pmids\": [\"22310711\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Rhinovirus ion channel protein 2B targets the ER and Golgi to trigger Ca2+ flux, which activates NLRP3 and NLRC5 inflammasomes cooperatively, leading to IL-1β secretion in bronchial cells.\",\n      \"method\": \"Virus deletion mutants, siRNA knockdown, Ca2+ flux measurements, IL-1β secretion assays in primary bronchial cells\",\n      \"journal\": \"American journal of respiratory cell and molecular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — virus mutants and siRNA in primary cells with defined readout; single lab\",\n      \"pmids\": [\"23815151\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"NLRC5 binds RIG-I via its N-terminal death domain (atypical CARD). This interaction is critical for robust antiviral responses against influenza virus, as NLRC5 extends and stabilizes RIG-I expression. The influenza NS1 protein binds to NLRC5 to suppress its function. NLRC5's antiviral activity is LRR-domain independent.\",\n      \"method\": \"Co-immunoprecipitation, interaction domain mapping, overexpression in A549 and human bronchial epithelial cells, viral replication assays\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP with domain mapping and functional viral assays; single lab\",\n      \"pmids\": [\"25404059\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"The solution NMR structure of the N-terminal effector domain of NLRC5 reveals a six α-helix bundle with a death fold. It is an atypical CARD (α-helix 3 replaced by a loop; α-helix 1 lacks characteristic interruption) with a distinct electrostatic surface. In vitro interaction experiments showed interaction with the tandem CARD of RIG-I.\",\n      \"method\": \"Solution NMR structure determination, in vitro interaction experiments\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — NMR structure with in vitro binding validation; single lab but rigorous structural method\",\n      \"pmids\": [\"24815518\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"NLRC5 exclusively transactivates classical and non-classical MHC class I genes through binding to a specific SXY enhancer module distinct from that occupied by CIITA. NLRC5 chromatin recruitment requires the enhanceosome factor RFX5; Rfx5-knockout mice phenocopy Nlrc5 deficiency in MHC class I expression. The S-box sequence within the SXY module is the essential feature conferring NLRC5 specificity.\",\n      \"method\": \"ChIP-sequencing, Rfx5-knockout mice and cells, Nlrc5/CIIta double-knockout mice, de novo motif discovery, reporter assays\",\n      \"journal\": \"PLoS genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — ChIP-seq with genetic KO validation, epistasis through double-KO mice, motif analysis and reporter confirmation; multiple orthogonal methods\",\n      \"pmids\": [\"25811463\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"NLRC5 undergoes K63-linked ubiquitination by TRAF2/6 at lysine 1,178 following LPS stimulation, leading to dissociation of the NLRC5-IKK complex and creating a coherent feedforward loop to sensitize NF-κB activation. The deubiquitinase USP14 removes polyubiquitin chains from NLRC5, restoring NLRC5-mediated inhibition of NF-κB signaling.\",\n      \"method\": \"Ubiquitination assays, site-directed mutagenesis (K1178), Co-immunoprecipitation, mathematical modeling, USP14 overexpression/knockdown\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — site-specific mutagenesis identifying ubiquitination site, identification of E3 ligase (TRAF2/6) and deubiquitinase (USP14), multiple orthogonal biochemical methods\",\n      \"pmids\": [\"26620909\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"NLRC5 promotes transcription of BTN3A1-3 genes through an atypical regulatory motif in their promoters, similar to MHC class I genes. Forced NLRC5 expression promotes BTN3A-dependent Vγ9Vδ2 T-cell-mediated killing of tumor cells.\",\n      \"method\": \"ChIP, reporter assays, NLRC5 overexpression in tumor cells, Vγ9Vδ2 T cell killing assays, BTN3A gene correlation analysis\",\n      \"journal\": \"iScience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus functional killing assay; single lab with multiple methods\",\n      \"pmids\": [\"33364588\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"HIV-1 Tat-induced miRNA-34a targets NLRC5 mRNA (validated by Argonaute immunoprecipitation), downregulating NLRC5 protein and resulting in increased NF-κB p65 expression and microglial activation. miR-34a mimic downregulated NLRC5; miR-34a inhibitor upregulated NLRC5.\",\n      \"method\": \"Argonaute immunoprecipitation, bioinformatics, miRNA mimic/inhibitor transfection, in vivo validation in HIV-1 transgenic rats and SIV-infected macaques\",\n      \"journal\": \"Brain, behavior, and immunity\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Argonaute IP validation of miR-34a/NLRC5 interaction plus in vivo confirmation; single lab\",\n      \"pmids\": [\"30872089\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"PRMT5 inhibits transcription of the NLRC5 gene in melanoma cells, thereby suppressing MHC class I antigen presentation. PRMT5 knockdown augmented NLRC5 expression and increased MHC class I abundance.\",\n      \"method\": \"PRMT5 knockdown/pharmacological inhibition (GSK3326595), gene expression analysis, MHC class I flow cytometry in melanoma cells\",\n      \"journal\": \"Science translational medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological and genetic inhibition of PRMT5 with defined NLRC5 transcriptional readout; single lab\",\n      \"pmids\": [\"32641491\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"SARS-CoV-2 ORF6 protein suppresses NLRC5 both transcriptionally (by blocking STAT1 signaling, reducing IRF1 and NLRC5 gene expression) and functionally (by blocking karyopherin complex-dependent nuclear import of NLRC5), thereby inhibiting MHC class I pathway induction.\",\n      \"method\": \"SARS-CoV-2 ORF6 overexpression, gene expression profiling in COVID-19 patients and infected cell lines, nuclear import assays, STAT1 signaling analysis\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — two distinct molecular mechanisms identified (transcriptional via STAT1 and nuclear import via karyopherin), validated in patient samples and cell lines\",\n      \"pmids\": [\"34782627\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"LC3 (autophagy protein) directly interacts with NLRC5 and inhibits NLRC5-mediated MHC class I antigen presentation pathway in endometrial cancer cells in vitro and in vivo. Autophagy upregulation correlates negatively with NLRC5 and MHC class I expression in endometrial cancer.\",\n      \"method\": \"Co-immunoprecipitation, autophagy modulation, MHC class I reporter assays, in vivo tumor model\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — Co-IP for LC3-NLRC5 interaction with functional MHC-I readout in vivo and in vitro; single lab\",\n      \"pmids\": [\"34974132\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"NLRC5 interacts with the dengue virus NS3 protease domain and recruits E3 ubiquitin ligase CUL2 to catalyze K48-linked poly-ubiquitination of NS3, which is then recognized by cargo receptor TOLLIP for selective autophagic degradation. This NLRC5-CUL2-NS3-TOLLIP axis restricts dengue virus infection.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assays, autophagy inhibitors, NLRC5 knockout, overexpression, viral replication assays\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — full mechanistic axis defined (NLRC5→CUL2→K48-Ub-NS3→TOLLIP→autophagic degradation) with Co-IP, ubiquitination assays, and KO validation\",\n      \"pmids\": [\"36126167\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"METTL3-mediated m6A modification of NLRC5 mRNA inhibits its YTHDF2-dependent degradation, thereby stabilizing NLRC5 and promoting MHC class I-mediated immunosurveillance in endometrial cancer. METTL3 depletion increased YTHDF2-dependent NLRC5 mRNA degradation.\",\n      \"method\": \"RNA immunoprecipitation (RIP), methylated RIP, RNA stability assays, METTL3 overexpression/depletion, YTHDF2 functional experiments, tumor mouse model\",\n      \"journal\": \"Biomarker research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — RIP and methylated-RIP with RNA stability and in vivo functional validation; single lab\",\n      \"pmids\": [\"37085864\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"NLRC5 regulates IFNα-induced alternative splicing and expression of HLA class I and antigen presentation genes in human pancreatic β cells, indicating a role beyond transcriptional activation of MHC class I to include regulation of alternative splicing events.\",\n      \"method\": \"Bulk and single-cell RNA sequencing, NLRC5 gain/loss-of-function in EndoC-βH1 and human islet cells\",\n      \"journal\": \"Science advances\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — RNA-seq with functional NLRC5 manipulation; single lab, novel splicing function identified\",\n      \"pmids\": [\"36103539\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"NLRC5 directly bound to NLRP3 and NLRC4 in inflammasomes (Co-IP) to cooperatively drive microglial pyroptosis (gasdermin D cleavage) and apoptosis. NLRC5 knockdown suppressed GSDMD cleavage, IL-1β and caspase-3 activation in a retinal ischemia model.\",\n      \"method\": \"Co-immunoprecipitation, NLRC5 knockdown, GSDMD/caspase-3/IL-1β assays in retinal ischemia model (in vivo and primary microglia)\",\n      \"journal\": \"Frontiers in cell and developmental biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — Co-IP for inflammasome complex interaction plus in vivo KD phenotype; single lab\",\n      \"pmids\": [\"34095138\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"NLRC5 interacts with HSPA8 in macrophages and suppresses the NF-κB pathway. Myeloid-specific deletion of NLRC5 aggravated pressure overload-induced cardiac remodeling and promoted IL-6 secretion, affecting cardiomyocyte hypertrophy and cardiac fibroblast activation.\",\n      \"method\": \"Co-immunoprecipitation (NLRC5-HSPA8), myeloid-specific Nlrc5 conditional KO mice, pressure overload model, NF-κB pathway analysis, IL-6 ELISA\",\n      \"journal\": \"JACC. Basic to translational science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP identifies HSPA8 as binding partner, conditional KO with defined cardiac phenotype; single lab\",\n      \"pmids\": [\"37325412\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"NLRC5 acts as an innate immune sensor driving PANoptosis (inflammatory cell death) in response to heme/PAMP and heme/cytokine combinations. NLRC5 interacted with NLRP12 and PANoptosome components to form a cell death complex. TLR signaling and NAD+ depletion regulated NLRC5 expression and ROS production to control PANoptosis. NLRC5-deficient mice were protected in hemolytic and inflammatory models.\",\n      \"method\": \"CRISPR-based NLRC5 knockout and reconstitution, Co-immunoprecipitation (NLRP12 and PANoptosome), cell death assays, ROS measurement, NLRC5-deficient mouse models\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — multiple orthogonal methods (KO, Co-IP, in vivo models), novel sensor function established in high-impact venue\",\n      \"pmids\": [\"38878777\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"USP14, a deubiquitinase, stabilizes NLRC5 by preventing its proteasomal degradation, thereby enhancing NLRC5-mediated inhibition of NF-κB signaling in endothelial cells. USP14 overexpression in ApoE-/- mice reduced atherosclerotic lesions.\",\n      \"method\": \"USP14 overexpression/knockdown, Co-immunoprecipitation, ubiquitination assays, NF-κB pathway analysis, ApoE-/- mouse model\",\n      \"journal\": \"Biochimica et biophysica acta. Molecular and cell biology of lipids\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP and ubiquitination assays with in vivo validation; single lab\",\n      \"pmids\": [\"36372300\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"USP14 promotes de-ubiquitination and stabilization of NLRC5, leading to Smad2/3 pathway activation and EndMT progression in atherosclerosis. USF1 transcriptionally activates USP14 to drive this USF1/USP14/NLRC5/Smad2/3 axis.\",\n      \"method\": \"Dual-luciferase reporter assay, ChIP, Co-immunoprecipitation, ubiquitination assays, shRNA knockdown, ApoE-/- mouse atherosclerosis model\",\n      \"journal\": \"Molecular medicine (Cambridge, Mass.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP, Co-IP, and luciferase assays defining the USF1→USP14→NLRC5→Smad2/3 axis; in vivo confirmation; single lab\",\n      \"pmids\": [\"38424494\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"NLRC5 is a multifunctional NLR protein that serves as the master transcriptional coactivator (CITA) of MHC class I and related antigen-presentation genes (β2m, TAP1, LMP2, BTN3A) by localizing to the nucleus and binding SXY enhancer motifs via the RFX5-containing enhanceosome; it also negatively regulates NF-κB and type I interferon signaling by interacting with IKKα/β and RIG-I/MDA5 respectively, with its activity dynamically controlled by TRAF2/6-mediated K63-ubiquitination (at K1178) and USP14-mediated deubiquitination; additionally, NLRC5 can form inflammasome/PANoptosome complexes with NLRP3, NLRP12, and ASC to drive caspase-1-dependent IL-1β processing and PANoptosis, and it restricts dengue virus by recruiting E3 ligase CUL2 to ubiquitinate viral NS3 for TOLLIP-mediated selective autophagic degradation.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"NLRC5 is a multifunctional NLR protein that serves as the master transcriptional coactivator of MHC class I antigen-presentation genes while also tuning innate immune signaling and inflammatory cell death [#1, #6, #15]. As an IFN-γ-inducible nuclear protein whose own expression depends on STAT1-mediated signaling, NLRC5 occupies the proximal promoters of MHC class I genes and coordinately drives β2-microglobulin, TAP, and LMP expression [#1, #6, #9]; its specificity arises from binding a distinct SXY enhancer module (notably the S-box) through the RFX5-containing enhanceosome, and Rfx5-knockout mice phenocopy Nlrc5 deficiency in MHC class I expression [#15]. This transactivation requires an intact nucleotide-binding domain and nuclear localization signal for nuclear import as well as the CARD and LRR domains [#6, #11], and extends to non-classical MHC class I and butyrophilin (BTN3A) genes that license γδ T-cell killing [#15, #17]. Genetic ablation in mice profoundly reduces MHC class I, especially in lymphocytes, and cripples CD8+ T-cell responses to Listeria [#6, #7, #8]. NLRC5 expression is itself a regulatory node controlled by PRMT5-mediated transcriptional repression, METTL3/YTHDF2 m6A-dependent mRNA stability, and miR-34a, and is targeted by viral immune evasion proteins including SARS-CoV-2 ORF6, which blocks both STAT1-driven induction and karyopherin-dependent nuclear import [#19, #23, #18, #20]. In parallel, NLRC5 negatively regulates NF-κB by directly binding IKKα/β to block their phosphorylation, an inhibitory interaction released by TRAF2/6-mediated K63-ubiquitination at K1178 and restored by USP14-mediated deubiquitination [#0, #16, #28]. NLRC5 also functions in inflammatory cell death, cooperating with NLRP3 to support caspase-1/IL-1β processing and acting as an innate sensor that assembles with NLRP12 and PANoptosome components to drive PANoptosis in response to heme/PAMP stimuli [#5, #27]. Beyond immunity, NLRC5 restricts dengue virus by recruiting the E3 ligase CUL2 to K48-ubiquitinate the viral NS3 protease for TOLLIP-mediated selective autophagic degradation [#22]. Reports of NLRC5 as a positive regulator of type I interferon responses conflict with knockout studies showing it is dispensable or inhibitory for type I IFN induction [#0, #3, #8, #9].\",\n  \"teleology\": [\n    {\n      \"year\": 2010,\n      \"claim\": \"Establishing whether NLRC5 functions as a brake on inflammatory signaling, the first studies showed it directly engages the IKK and RLR machinery to dampen NF-κB and type I interferon responses.\",\n      \"evidence\": \"Co-IP, siRNA knockdown, reporter and phosphorylation assays in HEK293T and other lines\",\n      \"pmids\": [\"20434986\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not reconcile with reports of NLRC5 as a positive antiviral regulator\", \"Mechanism of IKK phosphorylation block not structurally defined\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Defining NLRC5's nuclear function, it was identified as an IFN-γ-inducible nuclear factor that occupies MHC class I promoters and coordinately drives β2m, TAP, and LMP expression, establishing it as a transcriptional activator of antigen presentation.\",\n      \"evidence\": \"ChIP, reporter assays, siRNA knockdown and overexpression in lymphoid and epithelial lines\",\n      \"pmids\": [\"20639463\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cis-element specificity not yet mapped\", \"Co-factors mediating promoter recruitment unknown\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Addressing whether NLRC5 also acts cytosolically in inflammasomes and antiviral sensing, studies reported cooperativity with NLRP3 for caspase-1/IL-1β processing and conflicting positive roles in type I IFN induction.\",\n      \"evidence\": \"Reconstitution, Co-IP, caspase-1 cleavage and qPCR/ELISA in monocytic cells, THP-1, and fibroblasts\",\n      \"pmids\": [\"21191067\", \"20538593\", \"20610642\", \"20061403\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Positive versus negative roles in interferon signaling unresolved across cell types\", \"Inflammasome contribution single-lab\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"To distinguish in vivo physiological function, knockout mice demonstrated NLRC5 is specifically required for MHC class I (not class II) expression and CD8+ T-cell responses, with lymphocytes most affected, while remaining largely dispensable for NF-κB and type I IFN.\",\n      \"evidence\": \"Multiple independent Nlrc5-deficient mouse lines, ChIP, domain mutagenesis, flow cytometry, Listeria infection\",\n      \"pmids\": [\"22412192\", \"22711889\", \"22491475\", \"22473004\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cell-type basis of differential MHC I dependence unexplained\", \"KO data contradicted earlier positive IFN role reports\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Mapping the domains required for activity, the NBD and an intact NLS were shown to be essential for nuclear import and MHC class I transactivation.\",\n      \"evidence\": \"Domain deletion/mutagenesis with localization imaging and reporter assays\",\n      \"pmids\": [\"22310711\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Karyopherin partners mediating import not identified\", \"Single lab\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Resolving the structural basis of NLRC5's effector domain and its antiviral engagement, NMR revealed an atypical CARD that binds the tandem CARD of RIG-I, an interaction targeted by influenza NS1.\",\n      \"evidence\": \"Solution NMR structure, in vitro binding, Co-IP and domain mapping in airway epithelial cells\",\n      \"pmids\": [\"24815518\", \"25404059\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of RIG-I binding conflicts with negative regulation reports\", \"Stoichiometry of NLRC5-RIG-I complex undefined\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Determining the molecular basis of NLRC5 promoter specificity, ChIP-seq with genetic epistasis established that NLRC5 transactivates MHC class I exclusively via a distinct SXY/S-box module requiring the RFX5 enhanceosome.\",\n      \"evidence\": \"ChIP-seq, Rfx5-KO and Nlrc5/CIIta double-KO mice, motif discovery, reporter assays\",\n      \"pmids\": [\"25811463\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct DNA-binding versus enhanceosome-bridged recruitment not fully distinguished\", \"Full enhanceosome subunit composition for NLRC5 not enumerated\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Explaining how NLRC5's inhibitory activity is dynamically switched, K63-ubiquitination by TRAF2/6 at K1178 was shown to dissociate the NLRC5-IKK complex and sensitize NF-κB, with USP14 deubiquitination restoring inhibition.\",\n      \"evidence\": \"Site-directed mutagenesis, ubiquitination assays, Co-IP, mathematical modeling\",\n      \"pmids\": [\"26620909\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Spatial regulation of ubiquitination relative to nuclear pool unknown\", \"Crosstalk with transcriptional function not addressed\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Extending the transactivation program beyond classical MHC I, NLRC5 was shown to drive BTN3A1-3 expression and BTN3A-dependent Vγ9Vδ2 T-cell killing of tumor cells.\",\n      \"evidence\": \"ChIP, reporter assays, overexpression and γδ T-cell killing assays in tumor cells\",\n      \"pmids\": [\"33364588\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether BTN3A regulation uses the same S-box determinant not confirmed\", \"Single lab\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Establishing how NLRC5 protein and transcript levels are set, multiple regulatory inputs were defined: PRMT5 transcriptional repression, METTL3/YTHDF2 m6A-dependent mRNA stability, miR-34a targeting, and USP14-mediated proteasomal stabilization, the latter feeding NF-κB and Smad2/3 outputs in vascular disease.\",\n      \"evidence\": \"Knockdown/inhibition, RIP/meRIP, Argonaute IP, ChIP, ubiquitination assays in melanoma, endometrial cancer, microglia and ApoE-/- models\",\n      \"pmids\": [\"32641491\", \"37085864\", \"30872089\", \"36372300\", \"38424494\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Most regulatory axes shown in single disease contexts\", \"Hierarchy among these inputs unknown\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Defining NLRC5's roles in inflammatory cell death and viral restriction, it was shown to assemble with NLRP12/PANoptosome to sense heme/PAMP and drive PANoptosis, and to recruit CUL2 to K48-ubiquitinate dengue NS3 for TOLLIP-mediated autophagic degradation.\",\n      \"evidence\": \"CRISPR KO and reconstitution, Co-IP, cell death/ROS assays, ubiquitination assays, in vivo models\",\n      \"pmids\": [\"38878777\", \"36126167\", \"34095138\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How NLRC5 switches between nuclear transactivator and cytosolic sensor/scaffold roles is unresolved\", \"Sensor ligand-binding mechanism for heme not structurally defined\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unresolved how a single protein integrates its nuclear MHC class I transactivation, cytosolic NF-κB/RLR regulation, inflammasome/PANoptosome assembly, and antiviral ubiquitin-autophagy functions, and what governs the switch between these mutually exclusive activities.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified structural model of full-length NLRC5\", \"Signal-dependent partitioning between nucleus and cytosol mechanistically undefined\", \"Contradictory roles in type I IFN signaling unreconciled\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [1, 6, 15]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [1, 6, 15]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 16]},\n      {\"term_id\": \"GO:0140299\", \"supporting_discovery_ids\": [27]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [1, 6, 11]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [3, 2]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [1, 6, 8]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [1, 15]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 16]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [27, 25]},\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [22]}\n    ],\n    \"complexes\": [\n      \"RFX5 enhanceosome (SXY module)\",\n      \"NLRP3 inflammasome\",\n      \"PANoptosome (with NLRP12)\"\n    ],\n    \"partners\": [\n      \"RFX5\",\n      \"IKKA\",\n      \"IKKB\",\n      \"RIG-I\",\n      \"NLRP3\",\n      \"USP14\",\n      \"CUL2\",\n      \"NLRP12\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":9,"faith_pct":88.88888888888889}}